Email this article 
Features of ensuring the immunological safety of allogeneic transfusions in patients with hematological malignancies
- Authors: Moor Y.V.1,2, Prosvirina N.V.1,2, Babaeva T.N.2, Skvortsova N.V.2, Khalzov K.V.2, Pospelova T.I.2
-
Affiliations:
- Novosibirsk Clinical Blood Center
- Novosibirsk State Medical University, Ministry of Health of Russia
- Issue: Vol 21, No 2 (2026)
- Pages: 116-124
- Section: SUPPORTIVE THERAPY ASPECTS
- Published: 25.06.2026
- URL: https://oncohematology.abvpress.ru/ongm/article/view/1087
- DOI: https://doi.org/10.17650/1818-8346-2026-21-2-116-124
- ID: 1087
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
additional measures to ensure the immunological safety of allogeneic transfusions.
Aim. To study the features of ensuring the immunological safety of allogeneic transfusions in patients with hematological malignancies.
Materials and methods. For the period 2020–2024, the results of immunohematological studies of 10,276 blood samples from patients requiring individual selection of erythrocyte-containing components of donor blood were analyzed. Of these, 1129 (10.9 %) were oncohematological patients; 28 (0.3 %) were patients with established refractoriness to platelet concentrate transfusions requiring individual selection of this concentrate, of which oncohematological diseases were observed in 26 cases. All necessary studies were carried out at the immunological reference center of the Novosibirsk Clinical Blood Center.
Results. The proportion of oncohematological patients who required individual selection of erythrocyte-containing blood components was 10.8 % for patients with newly detected anti-erythrocyte antibodies and 11.1 % for those with previously established antibodies. In patients with hematological malignancies, polyspecificity of antibodies is significantly more common (83.1 % of all cases of polyspecificity) and difficult to identify (61.7 % of samples with unknown specificity). The selection of a single red blood cells dose requires significantly (2.2 times) more studies and compatibility testing, extended typing, and significant reserves of erythrocyte-containing blood components for clinical use. The effectiveness of individual selection of erythrocyte-containing blood components in an immunological reference center for oncohematological patients was 98.2 %.
Conclusion. Centralization of immunological testing at the Novosibirsk Clinical Blood Center has ensured the effectiveness of individual selection for patients with alloimmunization and antibody production to clinically significant antigens of erythrocyte-containing blood components in 99.7 % of cases, and individual selection of platelet concentrate for patients with transfusion refractoriness in 92.8 % of cases, including for patients with anti-HLA antibodies in 71.4 % of cases.
About the authors
Yulia V. Moor
Novosibirsk Clinical Blood Center; Novosibirsk State Medical University, Ministry of Health of Russia
Author for correspondence.
Email: nbb@nso.ru
ORCID iD: 0000-0002-4923-0435
Russian Federation, 2 / 1 Serafimovicha St., Novosibirsk 630054; 52 Krasny Prospekt, Novosibirsk 630091
N. V. Prosvirina
Novosibirsk Clinical Blood Center; Novosibirsk State Medical University, Ministry of Health of Russia
Email: nbb@nso.ru
ORCID iD: 0009-0002-8183-8624
Russian Federation, 2 / 1 Serafimovicha St., Novosibirsk 630054; 52 Krasny Prospekt, Novosibirsk 630091
T. N. Babaeva
Novosibirsk State Medical University, Ministry of Health of Russia
Email: nbb@nso.ru
ORCID iD: 0000-0002-2708-1133
Russian Federation, 52 Krasny Prospekt, Novosibirsk 630091
N. V. Skvortsova
Novosibirsk State Medical University, Ministry of Health of Russia
Email: nbb@nso.ru
ORCID iD: 0000-0001-6938-3802
Russian Federation, 52 Krasny Prospekt, Novosibirsk 630091
K. V. Khalzov
Novosibirsk State Medical University, Ministry of Health of Russia
Email: nbb@nso.ru
ORCID iD: 0000-0003-1665-3543
Russian Federation, 52 Krasny Prospekt, Novosibirsk 630091
T. I. Pospelova
Novosibirsk State Medical University, Ministry of Health of Russia
Email: nbb@nso.ru
ORCID iD: 0000-0001-6791-0314
Russian Federation, 52 Krasny Prospekt, Novosibirsk 630091
References
- Valiev T.T., Levashov A.S., Senzhapova E.R. Targeted drugs in pediatric oncology. Onkopediatriya = Oncopediatrics 2016;3(1):8–15. (In Russ.). doi: 10.15690/onco.v3i1.1524
- Valiev T.T. Innovative advances in pediatric oncology and hematology: data of 54th Congress of the International Society of Paediatric Oncology (SIOP). Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2022;9(4):125–8. (In Russ.). doi: 10.21682/2311-1267-2022-9-4-125-128
- Valiev T.T. Modern strategy for the diagnosis and treatment of non-Hodgkin’s lymphomas in children. Abstract dis. … doctor of medical sciences. Moscow, 2014. (In Russ.).
- Valiev T.T., Baryakh Е.A., Zeynalova P.A. et al. Optimization of diagnosis and treatment of Burkitt’s lymphoma in children, adolescents, and young adults. Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Basic Research and Clinical Practice 2014;7(2): 175–83. (In Russ.). doi: 10.21320/2500-2139-2014-7-2-175-183
- Parovichnikova E.N., Aleshina O.A., Troitskaya V.V. et al. Comparison of the treatment results in adult patients with acute Ph-negative lymphoblastic leukemia on protocols of the Russian multicenter studies ALL-2009 and ALL-2016. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2022;67(4):460–77. (In Russ.). doi: 10.35754/0234-5730-2022-67-4-460-477
- Valiev T.T. Diagnosis and treatment of acute lymphoblastic leukemia in children according to the BFM group protocols: a guide for physicians. Moscow: ID “MedINK”, 2025. (In Russ.).
- Gurieva O.D., Savelyeva M.I., Valiev T.T. Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review). Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2021;8(4):60–70. (In Russ.). doi: 10.21682/2311-1267-2021-8-4-60-70
- Valiev T.T., Shervashidze M.A., Belysheva T.S. Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002. Onkogematologiya = Oncohematology 2022;17(3):137–59. (In Russ.). doi: 10.17650/1818-8346-2022-17-3-137-159
- Rakhmani A.F., Mikhailova E.A., Dubinkin I.V. et al. Refractory to transfusions of donor platelets in patients with aplastic anemia and hemoblastosis. Onkogematologiya = Oncohematology 2018; 13(2):62–72. (In Russ.). doi: 10.17650/1818-8346-2018-13-2-62-72
- Order of the Ministry of Health of the Russian Federation dated October 20, 2020 No. 1134n “On approval of the procedure for medical examination of the recipient, conducting tests for individual compatibility, including a biological test, during transfusion of donor blood and (or) its components”. Available at: https://base.garant.ru/74900960/ (In Russ.)
- Krobinets I.I., Khromova E.B., Kim E.V. et al. Refractory to platelet concentrate transfusions in patients with oncological diseases. Kletochnaya terapiya i transplantologiya = Cellular Therapy and Transplantation 2025;14(S2):349. (In Russ.).
- Butina E.V., Sherstnev F.S., Maksimov O.D., Yovdiy A.V., Paramonov I.V. Role of HLA genes in development of HLA-alloimmunization in blood recipients. Klinicheskaya laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics 2022;67(5): 292–5. (In Russ.). doi: 10.51620/0869-2084-2022-67-5-292-295
- Gavrovskaya S.V., Krobinets I.I., Bodrova N.N. et al. Analysis of the possibility of selecting platelet donors for patients with refractoriness. Vestnik gematologii = Bulletin of Hematology 2025;(2):28–32. (In Russ.).
- Kalandarov R.S., Golovkina L.L., Vasilyeva M.N. et al. Genotyping of AB0 and Rh systems blood groups in patients after multiple hemotransfusions. Onkogematologiya = Oncohematology 2017; 12(2):70–9. (In Russ.). doi: 10.17650/1818-8346-2017-12-2-70-79
- Shatokhin Yu.V., Kudinova E.E., Ryabikina E.V. et al. Algorithm for oncohematological patients management during blood transfusions. Glavnyy vrach Yuga Rossii = Chief Physician in the South of Russia 2018;2(60):56–61. (In Russ.).
- Donskov S.I., Urtaev B.M., Dubinkin I.V. New tactics of blood transfusion therapy – from compatibility to identity: guide for specialists in industrial and clinical transfusiology. Moscow: BINOM, 2015. 270 p. (In Russ.).
- Gusachenko L.A., Chemakin Yu.A., Litovchenko O.G. Antired-cell antibodies of the Surgut city donors. Vestnik SurGU = Bulletin of Surgut State University 2018;4(22):63–7. (In Russ.).
- Litovchenko O.G., Gabidullina R.R., Gusachenko L.A., Chemakin Yu.A. Indicators of the frequency of alloimmune antibodies at certain titers of natural antibodies in blood donors of Surgut. Immunologiya = Immunology 2025;46(6):762–71. (In Russ.). doi: 10.33029/1816-2134-2025-46-6-762-771
- Yovdiy A.V., Butina E.V., Poponina E.A. Immunohematological provision of red blood cells transfusions to alloimmunized recipients (clinical case). Klinicheskaya laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics 2022;67(4):234–6. (In Russ.). doi: 10.51620/0869-2084-2022-67-4-234-236
- Gusachenko L.A., Litovchenko O.G. Immune antibodies in Moksha and Erzya ethnic groups of the Republic of Mordovia. Ekologiya cheloveka = Human Ecology 2020;27(6):22–8. (In Russ.). doi: 10.33396/1728-0869-2020-6-22-28
- Tilitskaya E.M., Semenov G.V., Dashkevich E.V. HLA-associated antiplatelet antibodies. Vestnik VGMU = Vitebsk Medical Journal 2021;20(1):24–30. (In Russ.). doi: 10.22263/2312-4156.2021.1.24
Supplementary files
